The study found that nearly all breast cancer related gene mutations

The study found that nearly all breast cancer related gene mutations

May 06, 2016 Source: Caixin Net

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

On May 2, 2016, Nature reported a recent study of breast cancer that found almost all genetic mutations that cause breast cancer, drug research for breast cancer, and breast cancer gene levels. Personalized treatment has a milestone.

Breast cancer is the most common cancer in women. According to the World Health Organization, there are 1.38 million new cases worldwide each year, and 458,000 people die from breast cancer.

Leading by the Sanger Research Institute in the United Kingdom, a team of scientists from multiple countries analyzed the entire genomic information from 560 breast cancer patients and found 93 possible tumor-associated genetic mutations, some of which have been discovered by previous studies. Scientists say that in addition to some particularly rare genetic mutations, the results of this study can be considered to cover all genes that may cause breast cancer.

In an interview with the British Broadcasting Corporation (BBC), Professor Michael Stratton of the Sanger Institute, who led the study, said the study was a landmark discovery in the field of cancer research. The human genome contains about 20,000 genes, and scientists have now discovered all the genes associated with breast cancer — one of the 93 genes that can cause breast cancer if it is mutated.

The research team will share the research results with universities, drug research centers, biotechnology companies, etc. to facilitate the development of new targeted drugs for breast cancer treatment.

In 1990, researchers discovered breast cancer numbers 1 and 2, called BRCA1 and BRCA2, on human chromosomes 17 and 13. What makes the BRCA gene known to the public is the removal of bilateral breast and ovarian and fallopian tubes after screening by Hollywood star Angelina Jolie. Julie's BRCA1 mutation test was positive, which means she has about 87% of breast cancer and 50% of ovarian cancer.

In recent years, as the cost of genetic testing has continued to decline, genetic screening for breast cancer-related genes in high-risk women has become a trend. It is foreseeable that as scientists find more mutations related to breast cancer, more precise genetic screening is about to be achieved.

The significance of this study is also the guiding significance of breast cancer treatment drugs, the British Cancer Institute commented.

In the past 15 years, many drugs for the treatment of breast cancer have been developed, and targeted drugs like Herceptin have been clinically applied to patients. Stratton believes that the development of new drugs based on this research will be applied to cancer patients and potentially high-risk groups for at least 10 years.

Another Sanger Institute researcher Selena who participated in the study? Dr. Serena Nik-Zainal said that in the future, researchers will be able to map the genomic mutations of individual individuals diagnosed with breast cancer and give more success based on individual circumstances. Rate of treatment options. This shows that the results of this research will be closer to the distance of personalized cancer treatment.

Although the intention of this study was to try to find all carcinogenic mutations that benefit all breast cancer patients, the results of the study herald a rather unfair future.

The study found that nearly 60% of breast cancer genetic mutations occur in 10 of these genes, which means that most of the research funding will be invested in the study of the 10 major genes, and those that occur less frequently, even rare The genetic disease caused by mutations in breast cancer is small, and the commercial prospects for developing drugs are insufficient. Relevant research may lack financial support.

Nucleic Acid Extraction system

Our Nucleic Acid Extractor has two models, one is NFAST 32A and the other is NFAST 96. NFAST 32A can extract up to 16 samples at a time, and NFAST96 can extract up to 96 samples at a time. Customers can choose the corresponding model according to their needs.

nucleic acid extractor,RNA extractor,DNA extractort,DNA extraction system,RNA extraction system

Shenzhen Uni-medica Technology Co.,Ltd , https://www.unimed-global.com